Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk
This article was originally published in The Tan Sheet
Executive Summary
FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.
You may also be interested in...
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
FDA Budget Request Reminds Congress: OTC Rulemakings Take Time
In its fiscal 2017 budget proposal, FDA responds to House and Senate appropriators' questions included in their reports on the agency's fiscal 2016 appropriation. Appropriators question why FDA has not approved additional OTC sunscreen active ingredients since Congress passed the Sunscreen Innovation Act in 2014.